Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

of leasehold

improvements - - 1,030

Depreciation and amortization 297 321 3,115

In-process research and

development - - 418

Total operating expenses 10,232 12,448 144,638

Loss from operations (10,232) (9,288) (139,694)

Other income (expenses):

Interest income 693 1,702 9,643

Interest expense (92) (70) (1,500)

Change in fair value of

warrant liability (64) - (454)

Other expense - - (1,180)

Loss before tax benefit (9,695) (7,656) (133,185)

(Provision for)/benefit

from income taxes - (75) 620

Net loss (9,695) (7,731) (132,565)

Deemed dividend - - (19,424)

Preferred stock accretion (41) - (802)

Net loss attributable to

common stockholders $(9,736) $ (7,731) $(152,791)

Net loss attributable to

common stockholders per

common share - basic and

diluted $ (10.21) $(0.34)

Weighted-average common

shares outstanding -

basic and diluted 953,959 22,412,689

See accompanying notes to consolidated financial statements

Table 2

Amicus Therapeutics, Inc.

Reconciliation of GAAP to non-GAAP Measures for the Statement of Operations Information for Three Months Ended March 31, 2008

(Unaudited)

(In thousands, except share and per share amounts) <
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
(Date:1/14/2014)... OTTAWA, Ontario , Jan. 14, 2014   Kinaxis ®, ... ( SCM ) and sales and operations planning ( S&OP ... the Biomanufacturing Summit , which will be held at ...  At the conference, join Kinaxis customer Elisabeth Kaszas , ...
(Date:1/14/2014)... 2014 During the 1600’s through the 1800’s ... Doctor’s Plague.” In this time period, doctors did not know ... times, to the death of vulnerable patients. In the same ... they may be unwittingly transmitting herpes viruses to their patients. ...
(Date:1/14/2014)... Holloway America today announced an addition to ... (MTRs) for all pressure vessels and tank parts the ... important for equipment that must meet ASME, CE, PED, ... functionality that allows authorized users to quickly locate and ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... Symbol: MS , , , ... Medical Corp. (TSX: MS), today announced that the University of Alberta , a major shareholder ... , , Certain employees, officers ... Alberta . , , , ...
... Smartfield, ... was approved for $250,000 for completion and commercialization of their SmartCrop® technology. SmartCrop is ... , ... 30, 2010 -- Smartfield, Inc. is an information company that develops and ...
... ATLANTA , April 29 Xoft, Inc., developer of ... therapy directly to cancer sites with minimal radiation exposure to surrounding ... for the treatment of skin cancer. The announcement was made here ... April 29-May 1 . , ...
Cached Biology Technology:BioMS Medical updates University of Alberta equity position 2$250,000 Awarded to Smartfield, Inc. of Lubbock, TX by the Texas Emerging Technology Fund 2Xoft's Electronic Brachytherapy Hits Milestone With 10 New Skin Cancer Installations 2Xoft's Electronic Brachytherapy Hits Milestone With 10 New Skin Cancer Installations 3Xoft's Electronic Brachytherapy Hits Milestone With 10 New Skin Cancer Installations 4
(Date:4/22/2014)... 2014 Scientists from the Florida campus of The ... that plays a critical but previously unknown role in ... showed a novel role for a protein known as ... eLife , a publisher supported by the Howard ... Wellcome Trust. , "This is a critical building block ...
(Date:4/22/2014)... nanotechnology expert will present a poster titled ... 7th International Nanotoxicology Congress to be held ... Monita Sharma will outline a strategy consistent with the ... " Toxicity Testing in the 21st Century: A Vision ... methods involving human cells and cell lines for mechanistic ...
(Date:4/22/2014)... Experimental Biology (FASEB) has released updated factsheets ... the National Institutes of Health (NIH) benefits each of ... pleased to make these factsheets available to help citizens ... state," said FASEB President, Margaret K. Offermann, MD, PhD. ... research funding, investing $29.2 billion in FY 2013 in ...
Breaking Biology News(10 mins):Scientists identify critical new protein complex involved in learning and memory 2
... This press release is available in French ... and men contribute equally to the lineage of contemporary populations? ... polygamy or monogamy? To answer these questions, Dr. Damian Labuda, ... a professor at the Department of Pediatrics of the Universit ...
... professor of chemistry at New Jersey Institute of ... patent today for a novel composition of matter. ... (US Patent Number 7,670,684) discloses a new self-contained ... comprised of organic scaffolds with metal centers, which ...
... worldwide. It is the most common form of age-related dementia, ... no cure, and the available drugs only help to relieve ... characteristic changes in the brains of Alzheimer,s patients is the ... curing or at least slowing the disease lies in developing ...
Cached Biology News:Modern man found to be generally monogamous, moderately polygamous 2NJIT researcher awarded patent for hydrophobic, corrosion-resistant coating 2The sea squirt offers hope for Alzheimer's sufferers 2
Candida (IgG) -Ab EIA Sample Size: 5 l...
Candida (IgA) -Ab EIA Sample Size: 5 l...
Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
... the first higher plant to be fully ... primary model organism for gene expression research ... microarray is derived from the ATH1 v.5 ... (TIGR) and from the Arabidopsis MPSS database ...
Biology Products: